|
1
|
Gellad ZF and Provenzale D: Colorectal
cancer: National and international perspective on the burden of
disease and public health impact. Gastroenterology. 138:2177–2190.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeon J, Du M, Schoen RE, Hoffmeister M,
Newcomb PA, Berndt SI, Caan B, Campbell PT, Chan AT, Chang-Claude
J, et al: Determining risk of colorectal cancer and starting age of
screening based on lifestyle, environmental, and genetic factors.
Gastroenterology. 154:2152–2164.e19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sjo OH, Berg M, Merok MA, Kolberg M,
Svindland A, Lothe RA and Nesbakken A: Peritoneal carcinomatosis of
colon cancer origin: Highest incidence in women and in patients
with right-sided tumors. J Surg Oncol. 104:792–797. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vermeer NC, Snijders HS, Holman FA,
Liefers GJ, Bastiaannet E, van de Velde CJ and Peeters KC:
Colorectal cancer screening: Systematic review of screen-related
morbidity and mortality. Cancer Treat Rev. 54:87–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mori F, Ferraiuolo M, Santoro R, Sacconi
A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P,
et al: Multitargeting activity of miR-24 inhibits long-term
melatonin anticancer effects. Oncotarget. 7:20532–20548. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yogin P, Nirav S, Lee JS, Markoutsa E, Jie
C, Liu S, Botbyl R, Reisman D, Xu P and Chen H: A novel
double-negative feedback loop between miR-489 and the
HER2-SHP2-MAPK signaling axis regulates breast cancer cell
proliferation and tumor growth. Oncotarget. 7:18295–18308.
2016.PubMed/NCBI
|
|
9
|
Konishi H, Fujiya M, Ueno N, Moriichi K,
Sasajima J, Ikuta K, Tanabe H, Tanaka H and Kohgo Y: microRNA-26a
and −584 inhibit the colorectal cancer progression through
inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem Biophys
Res Commun. 467:847–852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tili E, Michaille JJ and Calin GA:
Expression and function of micro-RNAs in immune cells during normal
or disease state. Int J Med Sci. 5:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kantharidis P, Wang B, Carew RM and Lan
HY: Diabetes complications: The microRNA perspective. Diabetes.
60:1832–1837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trionfini P and Benigni A: MicroRNAs as
master regulators of glomerular function in health and disease. J
Am Soc Nephrol. 28:1686–1696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kato M and Natarajan R: MicroRNAs in
diabetic nephropathy: Functions, biomarkers, and therapeutic
targets. Ann N Y Acad Sci. 1353:72–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Srivastava K and Srivastava A:
Comprehensive review of genetic association studies and
meta-analyses on miRNA polymorphisms and cancer risk. PLoS One.
7:e509662012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokarz P and Blasiak J: The role of
microRNA in metastatic colorectal cancer and its significance in
cancer prognosis and treatment. Acta Biochim Pol. 59:467–474. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Michael MZ, O' Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
18
|
Song B, Wang Y, Kudo K, Gavin EJ, Xi Y and
Ju J: miR-192 Regulates dihydrofolate reductase and cellular
proliferation through the p53-microRNA circuit. Clin Cancer Res.
14:8080–8086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Braun CJ, Zhang X, Savelyeva I, Wolff S,
Moll UM, Schepeler T, Ørntoft TF, Andersen CL and Dobbelstein M:
p53-Responsive micrornas 192 and 215 are capable of inducing cell
cycle arrest. Cancer Res. 68:10094–10104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vella S, Pomella S, Leoncini PP, Colletti
M, Conti B, Marquez VE, Strillacci A, Roma J, Gallego S, Milano GM,
et al: MicroRNA-101 is repressed by EZH2 and its restoration
inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clin
Epigenetics. 7:822015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser
GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al:
MicroRNA-101 inhibits human hepatocellular carcinoma progression
through EZH2 downregulation and increased cytostatic drug
sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo
YY, Mao H, Hao C, Olson JJ, Curran WJ and Wang Y: Targeting
DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS
One. 5:e113972010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buechner J, Tømte E, Haug BH, Henriksen
JR, Løkke C, Flægstad T and Einvik C: Tumour-suppressor microRNAs
let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell
proliferation in MYCN-amplified neuroblastoma. Br J Cancer.
105:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tuttle RM, Haugen B and Perrier ND:
Updated American Joint Committee on cancer/tumor-node-metastasis
staging system for differentiated and anaplastic thyroid cancer
(Eighth Edition): What changed and why? Thyroid. 27:751–756. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chuang-Bo Y, Tai-Ping H, Hai-Feng D,
Yong-Jun J, Xi-Rong Z, Guang-Ming M, Chenglong R, Jun W and Yong Y:
Quantitative assessment of the degree of differentiation in colon
cancer with dual-energy spectral CT. Abdom Radiol (NY).
42:2591–2596. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu G, Friggeri A, Yang Y, Park YJ,
Tsuruta Y and Abraham E: miR-147, a microRNA that is induced upon
Toll-like receptor stimulation, regulates murine macrophage
inflammatory responses. Proc Natl Acad Sci USA. 106:15819–15824.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gaidatzis D, van Nimwegen E, Hausser J and
Zavolan M: Inference of miRNA targets using evolutionary
conservation and pathway analysis. BMC Bioinformatics. 8:692007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Peer G, Lefever S, Anckaert J, Beckers
A, Rihani A, Van Goethem A, Volders PJ, Zeka F, Ongenaert M,
Mestdagh P and Vandesompele J: miRBase tracker: Keeping track of
microRNA annotation changes. Database (Oxford). 2014(pii):
bau0802014.PubMed/NCBI
|
|
32
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
eLife. 4:e050052015. View Article : Google Scholar :
|
|
33
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karp X and Ambros V: Developmental
biology. Encountering microRNAs in cell fate signaling. Science.
310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, et al: Downregulation of miR-138 is associated with
overexpression of human telomerase reverse transcriptase protein in
human anaplastic thyroid carcinoma cell lines. Cancer Sci.
99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen LG, Xia YJ and Cui Y: Upregulation of
miR-101 enhances the cytotoxic effect of anticancer drugs through
inhibition of colon cancer cell proliferation. Oncol Rep.
38:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gramantieri L, Ferracin M, Fornari F,
Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E,
Grazi GL, et al: Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma. Cancer
Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nicoloso MS and Calin GA: MicroRNA
involvement in brain tumors: From bench to bedside. Brain Pathol.
18:122–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schepeler T, Reinert JT, Ostenfeld MS,
Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ,
Kruhøffer M, Laurberg S, et al: Diagnostic and prognostic microRNAs
in stage II colon cancer. Cancer Res. 68:6416–6424. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Omerovic J, Laude AJ and Prior IA: Ras
proteins: Paradigms for compartmentalised and isoform-specific
signalling. Cell Mol Life Sci. 64:2575–2589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bonfrate L, Altomare DF, Di Lena M,
Travaglio E, Rotelli MT, De Luca A and Portincasa P: MicroRNA in
colorectal cancer: New perspectives for diagnosis, prognosis and
treatment. J Gastrointestin Liver Dis. 22:311–320. 2013.PubMed/NCBI
|
|
47
|
Frampton AE, Krell J, Gall TM, Castellano
L, Stebbing J and Jiao LR: miR-15b and miR-17 are tumor-derived
plasma microRNAs dysregulated in colorectal neoplasia. Ann Surg.
262:e61–e62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Diosdado B, van de Wiel MA, Terhaar Sive
Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B and Meijer
GA: MiR-17-92 cluster is associated with 13q gain and c-myc
expression during colorectal adenoma to adenocarcinoma progression.
Br J Cancer. 101:707–714. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chandramouli A, Onyeagucha BC,
Mercado-Pimentel ME, Stankova L, Shahin NA, LaFleur BJ, Heimark RL,
Bhattacharyya AK and Nelson MA: MicroRNA-101 (miR-101)
post-transcriptionally regulates the expression of EP4 receptor in
colon cancers. Cancer Biol Ther. 13:175–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Strillacci A, Valerii MC, Sansone P,
Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello
F, Campieri M and Spisni E: Loss of miR-101 expression promotes
Wnt/β-catenin signalling pathway activation and malignancy in colon
cancer cells. J Pathol. 229:379–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tsujii M and DuBois RN: Alterations in
cellular adhesion and apoptosis in epithelial cells overexpressing
prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Demir R, Naschberger L, Demir I, Melling
N, Dimmler A, Papadopoulus T, Sturzl M, Klein P and Hohenberger W:
Hypoxia generates a more invasive phenotype of tumour cells: An in
vivo experimental setup based on the chorioallantoic membrane.
Pathol Oncol Res. 15:417–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
